ATE369379T1 - Peptide und auf ihnen basierende pharmazeutische zusammensetzungen zur behandlung von störungen und krankheiten die mit der abnormalen proteinfaltung in amyloiden oder amyloid- ähnlichen ablagerungen zusammenhängen - Google Patents

Peptide und auf ihnen basierende pharmazeutische zusammensetzungen zur behandlung von störungen und krankheiten die mit der abnormalen proteinfaltung in amyloiden oder amyloid- ähnlichen ablagerungen zusammenhängen

Info

Publication number
ATE369379T1
ATE369379T1 AT96918482T AT96918482T ATE369379T1 AT E369379 T1 ATE369379 T1 AT E369379T1 AT 96918482 T AT96918482 T AT 96918482T AT 96918482 T AT96918482 T AT 96918482T AT E369379 T1 ATE369379 T1 AT E369379T1
Authority
AT
Austria
Prior art keywords
amyloid
deposits
peptides
diseases associated
disorders
Prior art date
Application number
AT96918482T
Other languages
English (en)
Inventor
Claudio Soto-Jara
Marc Baumann
Blas Frangione
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Application granted granted Critical
Publication of ATE369379T1 publication Critical patent/ATE369379T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AT96918482T 1995-06-07 1996-06-06 Peptide und auf ihnen basierende pharmazeutische zusammensetzungen zur behandlung von störungen und krankheiten die mit der abnormalen proteinfaltung in amyloiden oder amyloid- ähnlichen ablagerungen zusammenhängen ATE369379T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47832695A 1995-06-07 1995-06-07
US08/630,645 US5948763A (en) 1995-06-07 1996-04-10 Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits

Publications (1)

Publication Number Publication Date
ATE369379T1 true ATE369379T1 (de) 2007-08-15

Family

ID=27045861

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96918482T ATE369379T1 (de) 1995-06-07 1996-06-06 Peptide und auf ihnen basierende pharmazeutische zusammensetzungen zur behandlung von störungen und krankheiten die mit der abnormalen proteinfaltung in amyloiden oder amyloid- ähnlichen ablagerungen zusammenhängen

Country Status (8)

Country Link
US (3) US5948763A (de)
EP (1) EP0843516B1 (de)
JP (1) JP2001519753A (de)
AT (1) ATE369379T1 (de)
AU (1) AU715662B2 (de)
CA (1) CA2222690A1 (de)
DE (1) DE69637199T2 (de)
WO (1) WO1996039834A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US6942963B1 (en) 1997-01-10 2005-09-13 Massachusetts Institute Of Technology Methods for identifying treatments for neurotoxicity in Alzheimer's disease caused by β-amyloid peptides
CA2277519A1 (en) * 1997-01-10 1998-07-16 Massachusetts Institute Of Technology Treatments for neurotoxicity in alzheimer's disease by .beta.-amyloid peptides
DE19806055A1 (de) 1997-02-14 1998-08-27 Deutsches Krebsforsch Hemmung der Prion-Vermehrung durch dominant-negative Prionprotein-Mutanten
DE19725619A1 (de) * 1997-06-17 1998-12-24 Fraunhofer Ges Forschung Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien
GB9714276D0 (en) * 1997-07-08 1997-09-10 Univ Dundee Peptides and related compounds
US6472140B1 (en) * 1997-09-05 2002-10-29 The General Hospital Corporation α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease.
US6342350B1 (en) 1997-09-05 2002-01-29 The General Hospital Corporation Alpha-2-macroglobulin diagnostic test
EP1028317A4 (de) * 1997-10-02 2002-10-02 Akiko Itai Verfahren zum beeinflussen der dreidimensionalen struktur eines proteins
US8003612B2 (en) * 1997-10-08 2011-08-23 Proteotech Inc. Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein disorders
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7799535B1 (en) 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
US6211149B1 (en) 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
JP2002542151A (ja) * 1999-02-18 2002-12-10 科研製薬株式会社 成長ホルモン分泌促進物質としての新規なアミド誘導体
US7060670B1 (en) * 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7041807B1 (en) 1999-06-23 2006-05-09 Caprion Pharmaceuticals, Inc. Antibodies to a YYX epitope of a mammalian prion protein
DE60043165D1 (de) 1999-08-04 2009-11-26 Univ Southern California Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen
US6689753B1 (en) 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
AU781044B2 (en) * 1999-11-05 2005-05-05 Axonyx, Inc. Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof
EP1251837A2 (de) 1999-12-23 2002-10-30 Neurochem, Inc. Verbindungen und verfahren zur modulierung von amyloider gehirnangiopathie
AU2001274873B2 (en) 2000-05-22 2006-10-05 New York University Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits
AU6887101A (en) * 2000-06-20 2002-01-02 Caprion Pharmaceuticals, Inc. Copolymers and methods of treating prion-related diseases
US7067550B2 (en) * 2000-11-03 2006-06-27 Massachusetts Institute Of Technology Treatments for neurotoxicity in Alzheimer's Disease
WO2002035987A2 (en) * 2000-11-03 2002-05-10 Massachusetts Institute Of Technology METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES
US6716589B2 (en) * 2000-11-20 2004-04-06 Alphabeta Ab Discordant helix stabilization for prevention of amyloid formation
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
DE10104480A1 (de) * 2001-01-31 2002-08-14 November Ag Molekulare Medizin Verfahren, Verwendung und Kit zum Auffinden von Wirkstoffen gegen mit spezifischen Proteinen assoziierte Krankheiten
AU2002254328A1 (en) * 2001-03-20 2002-10-03 University Of Chicago Inhibitors and disassemblers of fibrillogenesis
US6613505B2 (en) 2001-04-12 2003-09-02 Bioresource International, Inc. Composition and method for destruction of infetious prion proteins
US7521479B2 (en) * 2001-04-16 2009-04-21 Panacea Pharmaceuticals, Inc. Methods of treating prion disease in mammals
EP1395833B1 (de) * 2001-05-31 2013-02-27 Adlyfe, Inc. Verfahren zum erkennen von inkorrekt gefalteten proteinen
EP1572894B1 (de) * 2001-11-21 2016-04-13 New York University Zu amyloid-beta, prionprotein, amylin, alpha-synuclein oder polyglutaminwiederholungen homologe synthetische immunogene, jedoch keine ablagerungen bildende polypeptide und peptide zur induzierung einer immunreaktion dagegen
WO2003059387A2 (en) * 2001-12-21 2003-07-24 Ilex Oncology, Inc. Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US20070021345A1 (en) 2003-06-30 2007-01-25 Ehud Gazit Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
AU2004203461B2 (en) * 2002-01-31 2009-09-03 Tel Aviv University Future Technology Development L.P. Peptides Antibodies Directed Thereagainst and Methods Using Same for Diagnosing and Treating Amyloid-Associated Diseases
EP1820806A1 (de) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinitätsbereiche
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
GB0209384D0 (en) * 2002-04-24 2002-06-05 Pepsyn Ltd Peptide composition
DE10221052A1 (de) * 2002-05-10 2003-12-04 Transmit Technologietransfer Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten
WO2003105677A2 (en) * 2002-06-01 2003-12-24 Praecis Pharmaceuticals, Inc. Methods for treating viral diseases using modulators of amyloidogenic peptide aggregation
DE10230141B4 (de) * 2002-07-04 2004-07-15 Priontype Gmbh Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)
EP1380290A1 (de) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-Beta-Strukturweg und seine therapeutische Relevanz
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
EP1567546A2 (de) * 2002-12-02 2005-08-31 Applied Research Systems ARS Holding N.V. Aza-peptiden
PT1953551E (pt) * 2002-12-03 2014-05-06 Pathogen Removal & Diagnostic Technologies Inc Ligandos a proteína de prião e métodos de uso
AU2003303198A1 (en) * 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
JP2007527365A (ja) * 2003-03-18 2007-09-27 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ アミリン凝集阻害剤およびその使用
US7632816B2 (en) * 2003-03-28 2009-12-15 New York University Treatment of Alzheimer amyloid deposition
US7335644B2 (en) * 2003-03-31 2008-02-26 Council Of Scientific And Industrial Research Anti-hypertensive molecules and process for preparation thereof
AU2004248302B2 (en) * 2003-06-19 2009-07-30 Merck Serono Sa Use of prion conversion modulating agents
NZ580256A (en) 2003-08-13 2011-07-29 Novartis Vaccines & Diagnostic Prion-specific peptide reagents comprising the sequence KKRPKPGG
US20080057057A1 (en) * 2004-03-18 2008-03-06 Applied Research Systems Ars Holding N.V. Anti-Lipid Rafts Antibodies
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
WO2006076497A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Osplation of pathogenic prions
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
BRPI0613525A2 (pt) * 2005-07-13 2011-05-31 Crossbeta Biosciences Bv métodos para produzir uma composição imunogênica, para melhorar a imunogenicidade de uma composição, para intensificar a imunogenicidade de uma composição de vacina, e para determinar a quantidade de estruturas beta-cruzadas em uma composição de vacina, usos de estruturas beta-cruzadas, e de uma composição imunogênica, vacina de subunidade, e, composição imunogênica
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
AU2006267176A1 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
EP1931695B1 (de) * 2005-09-09 2013-04-10 Novartis AG Prionspezifische Peptoidreagentien
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
DE112007001030T5 (de) * 2006-04-28 2009-02-26 Kagoshima University Amyloid-ß-Fibrillogenese-inhibierendes Peptid
WO2008022035A2 (en) * 2006-08-10 2008-02-21 The Scripps Research Institute Methods for identifying cellular modulators of disaggregation activity or aggregation activity in an animal
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2152744A4 (de) * 2007-04-26 2012-02-15 Univ Yale Prionprotein als rezeptor für amyloid-beta-oligomere
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
WO2009018625A1 (en) * 2007-08-09 2009-02-12 Sylvan Pharmaceuticals Pty Ltd. Treatment of prion protein related diseases
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2058000A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung
EP2058001A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Steigerung der Immunogenizität von Antigenen
EP2282753A1 (de) * 2008-04-30 2011-02-16 Novartis AG Assay für pathogene conformer
WO2009140683A1 (en) * 2008-05-16 2009-11-19 Research Foundation Of The City University Of New York Living copolymer protein/peptide hybrids for biomedical applications
EP2303315A1 (de) * 2008-05-22 2011-04-06 Ramot at Tel Aviv University Ltd. Verfahren zur behandlung von erkrankungen, die durch plaque gekennzeichnet sind
US20100099609A1 (en) * 2008-07-28 2010-04-22 Buck Institute For Age Research eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE
WO2010062570A2 (en) * 2008-10-27 2010-06-03 Recombinant Technologies Llc COMPOSITIONS COMPRISING CAPTURE PEPTIDES FOR A β-AMYLOID PEPTIDE
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010129674A2 (en) 2009-05-05 2010-11-11 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
EP2273273A1 (de) * 2009-07-11 2011-01-12 Rheinische Friedrich-Wilhelms-Universität Bonn Inhibitoren der Nitrierung von Amyloid-ß-Peptiden und ihre Verwendung bei der Diagnose und Behandlung von Morbus Alzheimer
TW201225972A (en) 2010-11-15 2012-07-01 Univ Ramot Dipeptide analogs for treating conditions associated with amyloid fibril formation
SG187271A1 (en) * 2011-07-07 2013-02-28 Agency Science Tech & Res Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic
WO2013013056A1 (en) 2011-07-19 2013-01-24 New York University Method for treating amyloid disease
US9926353B2 (en) 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
EP3560509B1 (de) 2011-12-22 2024-01-31 Children's Medical Center Corporation Aus saposin-a gewonnene peptide und verwendungen davon
EP3443008A1 (de) 2016-04-15 2019-02-20 Medimmune Limited Anti-prp-antikörper und verwendungen davon
CN114057858B (zh) 2020-08-10 2023-03-21 上海瑞吉康生物医药有限公司 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽
DE202022107272U1 (de) 2022-12-28 2023-01-30 Centurion University of Technology and Management Ein System zur Analyse der Infektion mit Pseudomonas Syringae durch gezielte Ansprache von Cochaperonen, die eine J-Domäne enthalten

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
ATE177754T1 (de) * 1991-12-03 1999-04-15 Proteus Molecular Design Fragmente von prion proteinen.
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
US6696061B1 (en) * 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
US6120765A (en) * 1993-04-02 2000-09-19 Shiseido Co. Ltd. Urokinase plasminogen activator fragments
US5470951A (en) * 1993-09-29 1995-11-28 City Of Hope Peptides for antagonizing the effects of amyloid βprotein
US5547931A (en) * 1994-02-23 1996-08-20 Immtech International Inc. Methods of stimulatory thrombocytopoiesis using modified C-reactive protein
JP3542181B2 (ja) * 1994-10-21 2004-07-14 日本たばこ産業株式会社 新規タンパク
DE19504302A1 (de) * 1995-02-09 1996-08-14 Boehringer Mannheim Gmbh Methode zur serologischen Typisierung mittels typspezifischer Antigene
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
WO1997021728A1 (en) * 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)

Also Published As

Publication number Publication date
AU715662B2 (en) 2000-02-10
EP0843516A1 (de) 1998-05-27
EP0843516A4 (de) 2002-08-14
CA2222690A1 (en) 1996-12-19
DE69637199T2 (de) 2008-04-24
AU6112996A (en) 1996-12-30
DE69637199D1 (de) 2007-09-20
JP2001519753A (ja) 2001-10-23
US5948763A (en) 1999-09-07
WO1996039834A1 (en) 1996-12-19
US20030087407A1 (en) 2003-05-08
US6462171B1 (en) 2002-10-08
EP0843516B1 (de) 2007-08-08

Similar Documents

Publication Publication Date Title
ATE369379T1 (de) Peptide und auf ihnen basierende pharmazeutische zusammensetzungen zur behandlung von störungen und krankheiten die mit der abnormalen proteinfaltung in amyloiden oder amyloid- ähnlichen ablagerungen zusammenhängen
Taylor et al. Development of a proteolytically stable retro-inverso peptide inhibitor of β-amyloid oligomerization as a potential novel treatment for Alzheimer’s disease
Tagliavini et al. Coexistence of Alzheimer's amyloid precursor protein and amyloid protein in cerebral vessel walls
DE602004009705T2 (de) Methoden der Verhinderung und Behandlung der Alzheimer'schen Krankheit
EA200101250A1 (ru) Предупреждение и терапия амилоидогенного заболевания
US5470951A (en) Peptides for antagonizing the effects of amyloid βprotein
PT721449E (pt) Inibidores da producao da proteina beta-amiloide
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
CY1111370T1 (el) Αποτροπη και θεραπεια αμυλοειδογονικης νοσου
DE69126304D1 (de) Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
EA200602015A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
CA2598080A1 (en) Amyloid-binding peptides, analogues and uses thereof
GEP20053423B (en) Method of Inhibiting Amyloid Protein Aggregation and Method for Imaging of Amyloid Deposits
EP1373502B8 (de) Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen
ATE215830T1 (de) Verfahren zur detektion und behandlung von individuen mit abnormal hla-a2/tyrosinase- peptidantigenen exprimierenden zellen
WO2001019851A3 (en) Opaminergic neuronal survival-promoting factors and uses thereof
KR940011479A (ko) 시클로 펩티드
EP1381627B1 (de) Polypeptide, abgeleitet von der amyloid vorläuferprotein (app), und ihre verwendungen
AU2003208857A8 (en) Diagnostic and therapeutic use of caps
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie
CA2315294A1 (fr) Utilisation de peptides citrullines derives de la filaggrine dans le cadre du traitement de maladies autoimmunes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties